ArticleJournal of clinical pathology2006
Clinical relevance of Fas expression in oesophageal squamous cell carcinoma.
Article in Journal of clinical pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review.Chinese journal of cancer · 2017Pooled it
- The role of CD95 and CD95 ligand in cancer.Cell death and differentiation · 2015Review
- p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal squamous cell carcinoma.Anti-cancer drugs · 2015Article
- Clinicopathological significance of BMP7 expression in esophageal squamous cell carcinoma.Annals of surgical oncology · 2012Article
- Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma.Clinical and experimental immunology · 2012Article
- Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.International orthopaedics · 2011Article
- Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma.BMC cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo determine the extent of Fas expression in oesophageal squamous cell carcinomas (ESCCs) from Chinese patients and to correlate Fas expression with clinicopathological prognostic parameters.
methodsClinicopathological data were collected from 58 patients with ESCC who underwent oesophagectomy and had no prior radiotherapy or chemotherapy. Immunostaining was performed on the primary tumours. Expression of Fas was correlated with patients' demographics, tumour characteristics and stage, R category of surgery, and patients' survival.
resultsThe actuarial survival rates of all patients at two and five years after surgery were 48% and 14%, respectively. Fas expression was detected in 89.7% of ESCCs. Higher Fas expression recorded on a four point scale correlated with better tumour differentiation (p < 0.01), but not with other patient or tumour variables. Importantly, higher Fas expression was associated with better survival (p = 0.0317).
conclusionsThese findings suggest that Fas activated apoptosis is important in the pathogenesis of ESCC. This molecular pathway may be a potential therapeutic target for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.